Prospects and challenges of building a cancer vaccine targeting telomerase

Dunn, 2004, The three Es of cancer immunoediting, Annu. Rev. Immunol., 22, 329, 10.1146/annurev.immunol.22.012703.104803 Van Der Bruggen, 2002, Tumor-specific shared antigenic peptides recognized by human T cells, Immunol. Rev., 188, 51, 10.1034/j.1600-065X.2002.18806.x Burnet, 1957, Cancer—a biological approach, Br. Med. J., 1, 841, 10.1136/bmj.1.5023.841 Dighe, 1994, Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors, Immunity, 1, 447, 10.1016/1074-7613(94)90087-6 Van Den Broek, 1996, Decreased tumor surveillance in perforin-deficient mice, J. Exp. Med., 184, 1781, 10.1084/jem.184.5.1781 Kaplan, 1998, Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice, Proc. Natl. Acad. Sci. USA, 95, 7556, 10.1073/pnas.95.13.7556 Shankaran, 2001, IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature, 410, 1107, 10.1038/35074122 Clark, 1989, Model predicting survival in stage I melanoma based on tumor progression, J. Natl. Cancer. Inst., 81, 1893, 10.1093/jnci/81.24.1893 Marrogi, 1997, Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma, Int. J. Cancer, 74, 492, 10.1002/(SICI)1097-0215(19971021)74:5<492::AID-IJC3>3.0.CO;2-Z Zhang, 2003, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, N. Engl. J. Med., 348, 201, 10.1056/NEJMoa020177 Pages, 2005, Effector memory T cells, early metastasis, and survival in colorectal cancer, N. Engl. J. Med., 353, 2654, 10.1056/NEJMoa051424 Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139 Van Pel, 1995, Genes coding for tumor antigens recognized by cytolytic T lymphocytes, Immunol. Rev., 145, 229, 10.1111/j.1600-065X.1995.tb00084.x Rosenberg, 1997, Cancer vaccines based on the identification of genes encoding cancer regression antigens, Immunol. Today, 18, 175, 10.1016/S0167-5699(97)84664-6 Van Pel, 1995, Genes coding for tumor antigens recognized by cytolytic T lymphocytes, Immunol. Rev., 145, 229, 10.1111/j.1600-065X.1995.tb00084.x Van Den Eynde, 1997, T cell defined tumor antigens, Curr. Opin. Immunol, 9, 684, 10.1016/S0952-7915(97)80050-7 Rosenberg, 2001, Progress in human tumour immunology and immunotherapy, Nature, 411, 380, 10.1038/35077246 Gilboa, 2004, The promise of cancer vaccines, Nat. Rev. Cancer, 4, 401, 10.1038/nrc1359 Novellino, 2005, A listing of human tumor antigens recognized by T cells: March 2004 update, Cancer Immunol. Immunother, 54, 187, 10.1007/s00262-004-0560-6 Jager, 1996, Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo, Int. J. Cancer, 66, 470, 10.1002/(SICI)1097-0215(19960516)66:4<470::AID-IJC10>3.0.CO;2-C Yee, 2000, Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo, J. Exp. Med, 192, 1637, 10.1084/jem.192.11.1637 Schmollinger, 2003, Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction, Proc. Natl. Acad. Sci. USA, 100, 3398, 10.1073/pnas.0530311100 Schultze, 2001, From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens, Trends Immunol, 22, 516, 10.1016/S1471-4906(01)02015-4 Vonderheide, 2002, Telomerase as a universal tumor-associated antigen for cancer immunotherapy, Oncogene, 21, 674, 10.1038/sj.onc.1205074 Hahn, 2001, Telomerase activation, cellular immortalization and cancer, Ann. Med., 33, 123, 10.3109/07853890109002067 Shay, 2002, Telomerase: a target for cancer therapeutics, Cancer Cell, 2, 257, 10.1016/S1535-6108(02)00159-9 Blackburn, 2001, Switching and signaling at the telomere, Cell, 106, 661, 10.1016/S0092-8674(01)00492-5 Cong, 2002, Human telomerase and its regulation, Microbiol. Mol. Biol. Rev., 66, 407, 10.1128/MMBR.66.3.407-425.2002 Kim, 1994, Specific association of human telomerase activity with immortal cells and cancer, Science, 266, 2011, 10.1126/science.7605428 Harley, 1990, Telomeres shorten during ageing of human fibroblasts, Nature, 345, 458, 10.1038/345458a0 Hastie, 1990, Telomere reduction in human colorectal carcinoma and with ageing, Nature, 346, 866, 10.1038/346866a0 Meyerson, 1997, hEST2, the putative human telomerase catalytic subunit gene, is up- regulated in tumor cells and during immortalization, Cell, 90, 785, 10.1016/S0092-8674(00)80538-3 Nakamura, 1997, Telomerase catalytic subunit homologs from fission yeast and human, Science, 277, 955, 10.1126/science.277.5328.955 Counter, 1994, Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes, J. Virol, 68, 3410, 10.1128/JVI.68.5.3410-3414.1994 Bodnar, 1998, Extension of life-span by introduction of telomerase into normal human cells, Science, 279, 349, 10.1126/science.279.5349.349 Vaziri, 1998, Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span, Curr. Biol., 8, 279, 10.1016/S0960-9822(98)70109-5 Hahn, 1999, Creation of human tumour cells with defined genetic elements, Nature, 400, 464, 10.1038/22780 Hahn, 1999, Inhibition of telomerase limits the growth of human cancer cells, Nat. Med, 5, 1164, 10.1038/13495 Herbert, 1999, Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death, Proc. Natl. Acad. Sci USA, 96, 14276, 10.1073/pnas.96.25.14276 Vonderheide, 1999, The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes, Immunity, 10, 673, 10.1016/S1074-7613(00)80066-7 Minev, 2000, Cytotoxic T cell immunity against telomerase reverse transcriptase in humans, Proc. Natl. Acad. Sci. USA, 97, 4796, 10.1073/pnas.070560797 Dupont, 2005, Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells, Cancer Res., 65, 5417, 10.1158/0008-5472.CAN-04-2991 Filaci, 2006, Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer, Blood, 107, 1505, 10.1182/blood-2005-01-0258 Parkhurst, 2004, Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase, Clin. Cancer Res., 10, 4688, 10.1158/1078-0432.CCR-04-0325 Ayyoub, 2001, Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing, Eur. J. Immunol., 31, 2642, 10.1002/1521-4141(200109)31:9<2642::AID-IMMU2642>3.0.CO;2-6 Gannage, 2005, Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy, J. Immunol., 174, 8210, 10.4049/jimmunol.174.12.8210 Hirano, 2006, Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia, Blood, 108, 2662, 10.1182/blood-2006-04-017566 Vonderheide, 2001, Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase, Clin. Cancer Res., 7, 3343 Arai, 2001, Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes, Blood, 97, 2903, 10.1182/blood.V97.9.2903 Scardino, 2002, HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy, J. Immunol, 168, 5900, 10.4049/jimmunol.168.11.5900 Hernandez, 2002, Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells, Proc. Natl. Acad. Sci. USA, 99, 12275, 10.1073/pnas.182418399 Adotevi, 2006, Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses, Clin, Cancer Res., 12, 3158, 10.1158/1078-0432.CCR-05-2647 Schreurs, 2005, Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope, Cancer Immunol. Immunother., 54, 703, 10.1007/s00262-004-0611-z Mizukoshi, 2006, Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma, Hepatology, 43, 1284, 10.1002/hep.21203 Cortez-Gonzalez, 2006, Immunogenic HLA-B7-restricted peptides of hTRT, Int. Immunol, 18, 1707, 10.1093/intimm/dxl105 Thorn, 2007, Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope, Cancer Immunol, Immunother, 10.1007/s00262-007-0319-y Nair, 2000, Induction of cytotoxic T lymphocyte responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells, Nat. Med, 6, 1011, 10.1038/79519 Heiser, 2001, Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors, Cancer Res., 61, 3388 Heiser, 2001, Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA, J. Immunol., 166, 2953, 10.4049/jimmunol.166.5.2953 Tourdot, 2000, A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes, Eur. J. Immunol., 30, 3411, 10.1002/1521-4141(2000012)30:12<3411::AID-IMMU3411>3.0.CO;2-R Gross, 2004, High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy, J. Clin. Invest., 113, 425, 10.1172/JCI200419418 Schroers, 2002, Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells, Cancer Res., 62, 2600 Schroers, 2003, Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes, Clin. Cancer Res., 9, 4743 Brunsvig, 2006, Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer, Cancer Immunol. Immunother., 55, 1553, 10.1007/s00262-006-0145-7 Kokhaei, 2007, Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells, Exp. Hematol., 35, 297, 10.1016/j.exphem.2006.10.006 Su, 2002, Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product, Cancer Res., 62, 5041 Frolkis, 2003, Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors, Cancer Gene Ther., 10, 239, 10.1038/sj.cgt.7700563 Maecker, 2005, Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients, Clin. Exp. Immunol., 141, 558, 10.1111/j.1365-2249.2005.02879.x Masutomi, 2002, Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma, Oncogene, 21, 5946, 10.1038/sj.onc.1205788 Marincola, 2003, Tumors as elusive targets of T-cell-based active immunotherapy, Trends Immunol., 24, 335, 10.1016/S1471-4906(03)00116-9 Lee, 1999, Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, Nat. Med., 5, 677, 10.1038/9525 Vonderheide, 2004, Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes, Clin. Cancer Res., 10, 828, 10.1158/1078-0432.CCR-0620-3 Domchek, 2006, Immunological and clinical outcomes following telomerase peptide vaccination in patients with metastatic breast cancer, Proc. AACR Bernhardt, 2006, Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study, Br, J. Cancer, 95, 1474, 10.1038/sj.bjc.6603437 Mavroudis, 2006, A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies, Oncology, 70, 306, 10.1159/000096252 Bolonaki, 2007, Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide, J. Clin. Oncol, 25, 2727, 10.1200/JCO.2006.10.3465 Cortez-Gonzalez, 2007, Telomerase immunity from bench to bedside: round one, J. Transl. Med, 5, 12, 10.1186/1479-5876-5-12 Su, 2005, Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer, J. Immunol, 174, 3798, 10.4049/jimmunol.174.6.3798 Drake, 2006, Mechanisms of immune evasion by tumors, Adv. Immunol, 90, 51, 10.1016/S0065-2776(06)90002-9 Lin, 2006, Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies, Int. J. Cancer, 119, 1886, 10.1002/ijc.22048 Chen, 2006, In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus, Biochem. Biophys. Res. Commun, 351, 927, 10.1016/j.bbrc.2006.10.165 Yamano, 2007, Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21, Cancer Gene Ther, 14, 451, 10.1038/sj.cgt.7701035 Kim, 2007, Direct vaccination with pseudotype baculovirus expressing murine telomerase induces anti-tumor immunity comparable with RNA-electroporated dendritic cells in a murine glioma model, Cancer Lett., 250, 276, 10.1016/j.canlet.2006.10.022 Guo, 2007, A novel peptide-nucleotide dual vaccine of human telomerase reverse transcriptase induces a potent cytotoxic T-cell response in vivo, Biochem. Biophys. Res. Commun, 357, 1090, 10.1016/j.bbrc.2007.04.056 Danet-Desnoyers, 2005, Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients, Exp. Hematol, 33, 1275, 10.1016/j.exphem.2005.07.011 Mitchell, 1999, A telomerase component is defective in the human disease dyskeratosis congenita, Nature, 402, 551, 10.1038/990141 Vulliamy, 2001, The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita, Nature, 413, 432, 10.1038/35096585 Yamaguchi, 2005, Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia, N. Engl. J. Med, 352, 1413, 10.1056/NEJMoa042980 Armanios, 2007, Telomerase mutations in families with idiopathic pulmonary fibrosis, N. Engl. J. Med, 356, 1317, 10.1056/NEJMoa066157